Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Healius Limited (HLS.AX)
AUD0.39
-0.01 (-2.50%)
AU ASX Healthcare Medical - Diagnostics & Research
Address
Liberty Place 2000
Sydney, NSW, AU
Sydney, NSW, AU
CEO
Paul D. Anderson
Website
healius.com.au
IPO
1998-08-03
ISIN AU0000033359
Description
Healius Limited is an Australian firm dedicated to delivering specialized diagnostic services to both individual consumers and healthcare practitioners. Its operations are structured into four primary segments: Pathology, Medical Imaging, Day Hospitals, and other miscellaneous services. The company's core offerings include comprehensive diagnostic imaging, private medical laboratory analysis, and various pathology services. Furthermore, under a diverse portfolio of brands such as Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetpath Laboratory, Vetnostics, QML Vetnostics, TML Vetnostics, ASAP Laboratory, Abbott Pathology, TML Pathology, IQ, Pathology, Kossard, Gastrolab, and Agilex Biolabs, alongside Lumus Imaging and Montserrat, Healius also facilitates a wide array of specialized surgical procedures. These encompass cataract removal, colonoscopies, gastroscopies, plastic and cosmetic operations, skin cancer excisions, IVF egg collection, and gynecological surgeries. The company boasts an extensive network across Australia, comprising 2,105 pathology facilities, 11 day hospitals, and 134 imaging centers. Established in 1994, the entity was originally known as Primary Health Care Limited, adopting the Healius Limited name in December 2018. Its corporate headquarters are situated in Sydney, Australia.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
AUD0.39
-0.01 (-2.50%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
5M
Beta
0.28
Float Shares
566.51M
Free Float %
78.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.86% | -6.85% | -32.67% | -50.36% | -65.31% | -62.43% | -61.14% | -88.24% | -91.26% | -90.26% | -62.14% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.39
DCF (Unlevered)
1.33
+241.6%
DCF (Levered)
6.62
+1,596.9%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
9% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 5 | 0 |
| Sell | 2 | 0 |
| Strong Sell | 3 | +1 |
Quality scores
Altman Z-Score
0.03
Distress
Piotroski F-Score
5 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Diagnostics & Research: +7.9%-23.0% Q4'25: -19.0% (vs Q4'23)
-
EPS growth Medical - Diagnostics & Research: +30.8%+26.5% Q4'25: +96.1% (vs Q4'23)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%-5.7% Q4'25: +10.6% (vs Q4'23)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+0.0% Q4'25: +1.1% (vs Q4'23)
-
ROIC Medical - Diagnostics & Research: +5.2%+0.0% Q4'25: +1.1% (vs Q4'23)
-
Share dilution Medical - Diagnostics & Research: 0.0%+10.1% Q4'25: +22.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×29.22× Q4'25: 3.40× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Jun 2000 actual |
Jun 2001 actual |
Jun 2002 actual |
Jun 2003 actual |
Jun 2004 actual |
Jun 2005 actual |
Jun 2006 actual |
Jun 2007 actual |
Jun 2008 actual |
Jun 2009 actual |
Jun 2010 actual |
Jun 2011 actual |
Jun 2012 actual |
Jun 2013 actual |
Jun 2014 actual |
Jun 2015 actual |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 10 Rev. Ana. 7 EPS Ana. |
Jun 2027 10 Rev. Ana. 6 EPS Ana. |
Jun 2028 9 Rev. Ana. 6 EPS Ana. |
Jun 2029 4 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 62.78M (-100.0%)
|
89.76M
est: 92.46M (-2.9%)
|
102.93M
est: 103.43M (-0.5%)
|
126.82M
est: 141.70M (-10.5%)
|
150.42M
est: 151.98M (-1.0%)
|
198.00M
est: 198.37M (-0.2%)
|
240.72M
est: 252.37M (-4.6%)
|
271.19M
est: 284.87M (-4.8%)
|
649.33M
est: 1.07B (-39.5%)
|
1.33B
est: 1.39B (-4.5%)
|
1.29B
est: 1.32B (-2.5%)
|
1.31B
est: 1.35B (-2.7%)
|
1.39B
est: 1.41B (-1.4%)
|
1.46B
est: 1.49B (-2.1%)
|
1.52B
est: 1.55B (-1.4%)
|
1.61B
est: 1.60B (+1.0%)
|
1.61B
est: 1.65B (-2.1%)
|
1.66B
est: 1.65B (+0.3%)
|
1.74B
est: 1.74B (-0.1%)
|
1.57B
est: 1.83B (-14.4%)
|
1.58B
est: 1.75B (-9.5%)
|
1.90B
est: 1.95B (-2.5%)
|
2.29B
est: 2.35B (-2.7%)
|
1.71B
est: 1.73B (-1.3%)
|
1.75B
est: 1.72B (+1.4%)
|
1.34B
est: 1.35B (-0.1%)
|
1.38B
1.37B – 1.39B
+2.5% YoY
|
1.43B
1.41B – 1.45B
+3.5% YoY
|
1.48B
1.48B – 1.48B
+3.9% YoY
|
1.50B
1.49B – 1.52B
+1.4% YoY
|
| EBITDA |
13.96M
est: 24.53M (-43.1%)
|
25.00M
est: 13.55M (+84.5%)
|
29.30M
est: 10.22M (+186.8%)
|
42.97M
est: 11.37M (+277.9%)
|
52.28M
est: 16.84M (+210.5%)
|
60.53M
est: 26.61M (+127.5%)
|
93.40M
est: 49.45M (+88.9%)
|
113.55M
est: 68.22M (+66.4%)
|
148.82M
est: 260.68M (-42.9%)
|
375.29M
est: -126.80M (+396.0%)
|
330.76M
est: -17.16M (+2,027.3%)
|
293.25M
est: 102.21M (+186.9%)
|
351.06M
est: 16.15M (+2,074.1%)
|
385.12M
est: 73.18M (+426.3%)
|
389.52M
est: 144.36M (+169.8%)
|
260.00M
est: 169.79M (+53.1%)
|
271.10M
est: -51.47M (+626.7%)
|
-333.10M
est: 35.24M (-1,045.1%)
|
179.80M
est: -584.25M (+130.8%)
|
167.80M
est: -5.15M (+3,356.5%)
|
300.80M
est: 50.90M (+491.0%)
|
470.40M
est: -147.12M (+419.7%)
|
734.80M
est: -151.34M (+585.5%)
|
-57.80M
est: -157.14M (+63.2%)
|
-298.10M
est: -159.36M (-87.1%)
|
31.20M
est: 104.15M (-70.0%)
|
106.71M
106.31M – 107.44M
+2.5% YoY
|
110.47M
109.33M – 112.30M
+3.5% YoY
|
114.76M
114.73M – 114.80M
+3.9% YoY
|
116.38M
115.56M – 117.75M
+1.4% YoY
|
| EBIT |
—
est: 30.39M (-100.0%)
|
15.31M
est: 16.79M (-8.8%)
|
15.42M
est: 17.18M (-10.2%)
|
24.62M
est: 22.33M (+10.3%)
|
30.93M
est: 28.21M (+9.6%)
|
48.16M
est: 42.11M (+14.4%)
|
74.14M
est: 63.21M (+17.3%)
|
92.43M
est: 85.22M (+8.5%)
|
108.85M
est: 351.09M (-69.0%)
|
307.51M
est: 141.84M (+116.8%)
|
257.66M
est: 291.57M (-11.6%)
|
211.06M
est: 263.01M (-19.8%)
|
265.19M
est: 221.34M (+19.8%)
|
294.42M
est: 280.05M (+5.1%)
|
295.57M
est: 304.88M (-3.1%)
|
229.30M
est: 320.56M (-28.5%)
|
114.40M
est: 75.04M (+52.5%)
|
-469.70M
est: 114.87M (-508.9%)
|
64.60M
est: -493.74M (+113.1%)
|
107.60M
est: 67.93M (+58.4%)
|
86.10M
est: 114.70M (-24.9%)
|
221.40M
est: 75.29M (+194.0%)
|
463.60M
est: 77.45M (+498.6%)
|
-335.00M
est: 80.42M (-516.5%)
|
-579.30M
est: 81.56M (-810.3%)
|
200.0K
est: 87.37M (-99.8%)
|
-57.31M
-57.71M – -57.10M
-165.6% YoY
|
-59.33M
-60.32M – -58.72M
-3.5% YoY
|
-61.64M
-61.66M – -61.62M
-3.9% YoY
|
-62.51M
-63.24M – -62.07M
-1.4% YoY
|
| Net Income |
5.44M
est: 14.40M (-62.2%)
|
6.33M
est: 7.95M (-20.5%)
|
6.33M
est: 7.07M (-10.5%)
|
12.59M
est: 8.63M (+45.9%)
|
18.04M
est: 13.51M (+33.5%)
|
27.94M
est: 23.25M (+20.1%)
|
47.48M
est: 35.56M (+33.5%)
|
56.90M
est: 53.83M (+5.7%)
|
6.78M
est: 214.34M (-96.8%)
|
108.50M
est: 8.82M (+1,130.7%)
|
132.00M
est: 102.88M (+28.3%)
|
78.29M
est: 134.51M (-41.8%)
|
116.62M
est: 82.10M (+42.0%)
|
150.11M
est: 123.13M (+21.9%)
|
162.54M
est: 155.44M (+4.6%)
|
127.50M
est: 170.73M (-25.3%)
|
38.40M
est: 131.78M (-70.9%)
|
-516.80M
est: 75.21M (-787.2%)
|
4.10M
est: -543.25M (+100.8%)
|
55.30M
est: 4.31M (+1,182.6%)
|
-70.50M
est: 54.61M (-229.1%)
|
43.70M
est: -69.84M (+162.6%)
|
307.90M
est: -71.85M (+528.5%)
|
-367.80M
est: -380.00M (+3.2%)
|
-645.80M
est: -636.00M (-1.5%)
|
-151.20M
est: -26.80M (-464.1%)
|
-8.99M
-16.77M – -1.22M
+66.4% YoY
|
-2.05M
-14.24M – 14.24M
+77.2% YoY
|
7.07M
-14.55M – 36.37M
+444.4% YoY
|
11.62M
11.51M – 11.80M
+64.3% YoY
|
| SGA |
—
est: 12.63M (-100.0%)
|
37.17M
est: 38.15M (-2.6%)
|
43.43M
est: 41.76M (+4.0%)
|
54.07M
est: 59.46M (-9.1%)
|
62.95M
est: 56.95M (+10.5%)
|
57.54M
est: 84.09M (-31.6%)
|
96.60M
est: 97.37M (-0.8%)
|
109.95M
est: 150.95M (-27.2%)
|
385.58M
est: 560.91M (-31.3%)
|
701.84M
est: 602.22M (+16.5%)
|
683.20M
est: 704.69M (-3.1%)
|
713.54M
est: 733.90M (-2.8%)
|
720.80M
est: 766.04M (-5.9%)
|
744.74M
est: 798.23M (-6.7%)
|
178.40M
est: 807.77M (-77.9%)
|
183.20M
est: 859.44M (-78.7%)
|
208.60M
est: 933.09M (-77.6%)
|
237.50M
est: 984.62M (-75.9%)
|
243.90M
est: 1.11B (-78.0%)
|
224.50M
est: 1.24B (-81.9%)
|
270.30M
est: 1.24B (-78.2%)
|
284.60M
est: 935.52M (-69.6%)
|
305.10M
est: 962.36M (-68.3%)
|
246.80M
est: 999.27M (-75.3%)
|
931.40M
est: 1.01B (-8.1%)
|
60.20M
est: 270.58M (-77.8%)
|
277.21M
276.19M – 279.12M
+2.5% YoY
|
286.99M
284.03M – 291.74M
+3.5% YoY
|
298.15M
298.05M – 298.25M
+3.9% YoY
|
302.34M
300.21M – 305.91M
+1.4% YoY
|
| EPS |
0.05
est: 0.10 (-46.0%)
|
0.06
est: 0.08 (-25.9%)
|
0.05
est: 0.10 (-50.4%)
|
0.09
est: 0.11 (-17.7%)
|
0.13
est: 0.15 (-14.6%)
|
0.18
est: 0.21 (-15.7%)
|
0.29
est: 0.40 (-27.3%)
|
0.33
est: 0.44 (-24.9%)
|
0.02
est: 0.27 (-91.8%)
|
0.26
est: 0.28 (-5.9%)
|
0.25
est: 0.30 (-16.5%)
|
0.14
est: 0.21 (-32.2%)
|
0.21
est: 0.24 (-11.1%)
|
0.27
est: 0.30 (-8.6%)
|
0.29
est: 0.32 (-9.2%)
|
0.24
est: 0.21 (+15.2%)
|
0.13
est: 0.12 (+9.7%)
|
-0.99
est: 0.12 (-952.7%)
|
0.01
est: 0.11 (-92.6%)
|
0.10
est: 0.11 (-9.5%)
|
-0.11
est: 0.07 (-265.4%)
|
0.06
est: 0.17 (-62.3%)
|
0.46
est: 0.35 (+30.4%)
|
-0.61
est: 0.03 (-1,907.8%)
|
-0.98
est: -0.01 (-12,352.4%)
|
-0.78
est: -0.03 (-2,240.2%)
|
-0.02
-0.02 – 0.00
+52.3% YoY
|
0.00
-0.02 – 0.02
+77.9% YoY
|
0.01
-0.02 – 0.05
+324.6% YoY
|
0.02
0.02 – 0.02
+102.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-28 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-27 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-26 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-25 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-22 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-21 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-20 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-19 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-18 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-15 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-14 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-13 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-12 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-01 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
48.94M
OE per share TTM
0.07
Owner's Yield
19.82%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
60.1%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 35 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares S&P/ASX Small Ordinaries ETF ISO.AX | 0.10% | 87.4K | 0.55% |
| 2 | iShares International Small-Cap Equity Factor ETF ISCF | 0.09% | 565.8K | 0.24% |
| 3 | BetaShares - FTSE RAFI Australia 200 ETF QOZ.AX | 0.04% | 337.3K | 0.40% |
| 4 | Dimensional - International Small Cap Value ETF DISV | 0.02% | 739.5K | 0.42% |
| 5 | State Street SPDR S&P International Small Cap ETF GWX | 0.02% | 132.6K | 0.40% |
| 6 | Schwab Fundamental International Small Company Index ETF FNDC | 0.01% | 433.9K | 0.39% |
| 7 | Vanguard Australian Shares Index ETF VAS.AX | 0.01% | 1.54M | 0.07% |
| 8 | Dimensional - International Small Cap ETF DFIS | 0.01% | 387.2K | 0.39% |
| 9 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 571.7K | 0.06% |
| 10 | Avantis Responsible International Equity ETF AVSD | 0.00% | 15.8K | 0.23% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
46.00
Shares Outstanding
726.16M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Paul D. Anderson | MD, Chief Executive Officer & Director | 3M | male |
| John McKechnie | Advisor | 898.2K | male |
| Kylie Brown | Group General Counsel, Company Secretary & Chief Risk Officer | — | female |
| Paula Bayliss | Group Executive of People & Culture | — | female |
| Phil Lucas | Chief Executive of Lumus Imaging | — | — |
| Prasad Arav | Group Executive of Digital & Technology and Strategy | — | male |
| Puneet Nagi | Chief Operating Officer | — | male |
| Andrew Thomson | Chief Financial Officer & Company Secretary | — | male |
| Sharon Ng | Head of FP&A and Investor Relations | — | — |
| Ian Mcphan | Chief Operating Officer of Healius Pathology | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for HLS.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
